Which has higher earnings and valuation, GRFS or ABSI?

Grifols has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.62 $454.82M $0.19 40.95 Absci $1.56M 1,009.24 -$115.18M -$0.80 N/A

Is GRFS or ABSI more profitable?

Grifols has a net margin of 5.54% compared to Absci's net margin of -7,756.38%. Grifols' return on equity of 6.21% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Absci -7,756.38% -61.71% -54.52%

Does the media refer more to GRFS or ABSI?

In the previous week, Absci had 17 more articles in the media than Grifols. MarketBeat recorded 21 mentions for Absci and 4 mentions for Grifols. Grifols' average media sentiment score of 1.22 beat Absci's score of 0.00 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CRSP or ABSI?

In the previous week, Absci had 18 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Absci and 3 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.90 beat Absci's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ACAD or ABSI?

In the previous week, Absci had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 21 mentions for Absci and 17 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.89 beat Absci's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is DYN or ABSI more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Absci -7,756.38% -61.71% -54.52%

Does the media favor DYN or ABSI?

In the previous week, Absci had 19 more articles in the media than Dyne Therapeutics. MarketBeat recorded 21 mentions for Absci and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Absci's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CELC or ABSI?

Absci has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Absci $1.56M 1,009.24 -$115.18M -$0.80 N/A

Is CELC or ABSI more profitable?

Celcuity has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -250.68% -50.23% Absci -7,756.38% -61.71% -54.52%

Does the media favor CELC or ABSI?

In the previous week, Celcuity had 2 more articles in the media than Absci. MarketBeat recorded 23 mentions for Celcuity and 21 mentions for Absci. Celcuity's average media sentiment score of 0.49 beat Absci's score of 0.00 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 8 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Absci 1 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Absci (ABSI) Competitors

$9.18 -0.28 (-2.96%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$9.13 -0.05 (-0.58%)

As of 08/14/2026 07:59 PM Eastern

Compare

ABSI vs. GRFS, CRSP, ACAD, DYN, and CELC

Should you buy Absci stock or one of its competitors? Absci's main competitors and comparable companies include Grifols (GRFS), CRISPR Therapeutics (CRSP), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Absci compare to Grifols?

Grifols (NASDAQ:GRFS) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Grifols presently has a consensus price target of $10.00, suggesting a potential upside of 28.53%. Absci has a consensus price target of $13.43, suggesting a potential upside of 46.28%. Given Absci's stronger consensus rating and higher probable upside, analysts clearly believe Absci is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Absci had 17 more articles in the media than Grifols. MarketBeat recorded 21 mentions for Absci and 4 mentions for Grifols. Grifols' average media sentiment score of 1.22 beat Absci's score of 0.00 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

52.0% of Absci shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Grifols has a net margin of 5.54% compared to Absci's net margin of -7,756.38%. Grifols' return on equity of 6.21% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Absci	-7,756.38%	-61.71%	-54.52%

Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Grifols has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.62	$454.82M	$0.19	40.95
Absci	$1.56M	1,009.24	-$115.18M	-$0.80	N/A

Summary

Grifols and Absci tied by winning 8 of the 16 factors compared between the two stocks.

How does Absci compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Absci had 18 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 21 mentions for Absci and 3 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.90 beat Absci's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Absci has lower revenue, but higher earnings than CRISPR Therapeutics. Absci is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,475.14	-$581.60M	-$4.76	N/A
Absci	$1.56M	1,009.24	-$115.18M	-$0.80	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Absci shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 10.5% of Absci shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics has a net margin of -3,368.72% compared to Absci's net margin of -7,756.38%. CRISPR Therapeutics' return on equity of -24.39% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Absci	-7,756.38%	-61.71%	-54.52%

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Absci has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 27.09%. Absci has a consensus target price of $13.43, suggesting a potential upside of 46.28%. Given Absci's stronger consensus rating and higher probable upside, analysts clearly believe Absci is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

CRISPR Therapeutics beats Absci on 10 of the 17 factors compared between the two stocks.

How does Absci compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Absci had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 21 mentions for Absci and 17 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.89 beat Absci's score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 52.0% of Absci shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

ACADIA Pharmaceuticals presently has a consensus price target of $33.69, suggesting a potential upside of 19.31%. Absci has a consensus price target of $13.43, suggesting a potential upside of 46.28%. Given Absci's higher possible upside, analysts plainly believe Absci is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Absci's net margin of -7,756.38%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Absci	-7,756.38%	-61.71%	-54.52%

ACADIA Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.54	$391M	$2.22	12.72
Absci	$1.56M	1,009.24	-$115.18M	-$0.80	N/A

Summary

ACADIA Pharmaceuticals beats Absci on 12 of the 16 factors compared between the two stocks.

How does Absci compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Dyne Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 33.92%. Absci has a consensus target price of $13.43, indicating a potential upside of 46.28%. Given Absci's higher possible upside, analysts clearly believe Absci is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Absci had 19 more articles in the media than Dyne Therapeutics. MarketBeat recorded 21 mentions for Absci and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Absci's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Absci has higher revenue and earnings than Dyne Therapeutics. Absci is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Absci	$1.56M	1,009.24	-$115.18M	-$0.80	N/A

Dyne Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Absci	-7,756.38%	-61.71%	-54.52%

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Absci shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Dyne Therapeutics and Absci tied by winning 8 of the 16 factors compared between the two stocks.

How does Absci compare to Celcuity?

Celcuity (NASDAQ:CELC) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Celcuity had 2 more articles in the media than Absci. MarketBeat recorded 23 mentions for Celcuity and 21 mentions for Absci. Celcuity's average media sentiment score of 0.49 beat Absci's score of 0.00 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	8 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Absci	1 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Celcuity has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Absci has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Absci	$1.56M	1,009.24	-$115.18M	-$0.80	N/A

Celcuity has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-250.68%	-50.23%
Absci	-7,756.38%	-61.71%	-54.52%

Celcuity currently has a consensus price target of $153.64, indicating a potential upside of 67.00%. Absci has a consensus price target of $13.43, indicating a potential upside of 46.28%. Given Celcuity's stronger consensus rating and higher probable upside, equities analysts plainly believe Celcuity is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Celcuity beats Absci on 9 of the 15 factors compared between the two stocks.

Get Absci News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABSI vs. The Competition

Export

Metric	Absci	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.58B	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	-11.48	10.77	271.26	25.40
Price / Sales	1,009.24	1,367.37	623.44	105.59
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	6.42	16.78	12.92	6.21
Net Income	-$115.18M	-$13.32M	$3.45B	$347.71M
7 Day Performance	2.80%	1.76%	1.16%	1.08%
1 Month Performance	11.54%	2.86%	2.17%	1.87%
1 Year Performance	213.31%	54.10%	62.38%	20.79%

Absci Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABSI Absci	2.3319 of 5 stars	$9.18 -3.0%	$13.43 +46.3%	+213.3%	$1.58B	$1.56M	N/A	210	News Coverage Earnings Report Analyst Forecast
GRFS Grifols	4.9577 of 5 stars	$8.05 +1.4%	$10.00 +24.2%	-27.4%	$5.40B	$7.42B	42.37	25,247	Positive News Short Interest Decrease
CRSP CRISPR Therapeutics	3.5987 of 5 stars	$53.51 0.0%	$68.06 +27.2%	-10.3%	$5.17B	$3.51M	N/A	460
ACAD ACADIA Pharmaceuticals	4.6514 of 5 stars	$29.39 +0.6%	$33.31 +13.3%	+11.5%	$5.03B	$1.07B	13.24	510	Analyst Forecast
DYN Dyne Therapeutics	3.7484 of 5 stars	$26.50 +1.0%	$34.42 +29.9%	+107.6%	$4.90B	N/A	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABSI) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Absci (ABSI) Competitors

ABSI vs. GRFS, CRSP, ACAD, DYN, and CELC

How does Absci compare to Grifols?

Summary

How does Absci compare to CRISPR Therapeutics?

Summary

How does Absci compare to ACADIA Pharmaceuticals?

Summary

How does Absci compare to Dyne Therapeutics?

Summary

How does Absci compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Absci (ABSI) Competitors

ABSI vs. GRFS, CRSP, ACAD, DYN, and CELC

How does Absci compare to Grifols?

Do analysts rate GRFS or ABSI?

Does the media refer more to GRFS or ABSI?

Do insiders and institutionals have more ownership in GRFS or ABSI?

Is GRFS or ABSI more profitable?

Which has more volatility and risk, GRFS or ABSI?

Which has higher earnings and valuation, GRFS or ABSI?

Summary

How does Absci compare to CRISPR Therapeutics?

Does the media refer more to CRSP or ABSI?

Which has preferable earnings & valuation, CRSP or ABSI?

Do insiders & institutionals have more ownership in CRSP or ABSI?

Is CRSP or ABSI more profitable?

Which has more risk and volatility, CRSP or ABSI?

Do analysts prefer CRSP or ABSI?

Summary

How does Absci compare to ACADIA Pharmaceuticals?

Does the media refer more to ACAD or ABSI?

Do insiders and institutionals have more ownership in ACAD or ABSI?

Which has more risk & volatility, ACAD or ABSI?

Do analysts prefer ACAD or ABSI?

Is ACAD or ABSI more profitable?

Which has stronger valuation & earnings, ACAD or ABSI?

Summary

How does Absci compare to Dyne Therapeutics?

Do analysts prefer DYN or ABSI?

Does the media favor DYN or ABSI?

Which has preferable earnings and valuation, DYN or ABSI?

Which has more risk and volatility, DYN or ABSI?

Is DYN or ABSI more profitable?

Do insiders & institutionals have more ownership in DYN or ABSI?

Summary

How does Absci compare to Celcuity?

Does the media favor CELC or ABSI?

Which has more volatility and risk, CELC or ABSI?

Do institutionals and insiders have more ownership in CELC or ABSI?

Which has stronger valuation and earnings, CELC or ABSI?

Is CELC or ABSI more profitable?

Do analysts prefer CELC or ABSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABSI vs. The Competition

Absci Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools